Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys $48,015.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 5,500 shares of the business’s stock in a transaction on Friday, April 4th. The shares were acquired at an average price of $8.73 per share, for a total transaction of $48,015.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,558,002 shares in the company, valued at approximately $48,521,357.46. This represents a 0.10 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

• On Monday, April 7th, Snehal Patel purchased 3,600 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $9.10 per share, for a total transaction of $32,760.00.
• On Friday, January 10th, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $12.51 per share, for a total transaction of $31,275.00.
• On Tuesday, January 7th, Snehal Patel bought 1,800 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $13.75 per share, for a total transaction of $24,750.00.

Greenwich LifeSciences Stock Up 4.0 %

Shares of NASDAQ:GLSI opened at $9.43 on Thursday. Greenwich LifeSciences, Inc. has a twelve month low of $8.06 and a twelve month high of $18.75. The stock’s 50 day moving average is $11.34 and its 200-day moving average is $12.62. The firm has a market capitalization of $123.96 million, a price-to-earnings ratio of -11.79 and a beta of 1.76.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.

Hedge Funds Weigh In On Greenwich LifeSciences

Several large investors have recently bought and sold shares of GLSI. State Street Corp increased its holdings in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after acquiring an additional 3,005 shares during the last quarter. Barclays PLC grew its holdings in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after purchasing an additional 6,538 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after purchasing an additional 5,861 shares in the last quarter. Garden State Investment Advisory Services LLC purchased a new position in shares of Greenwich LifeSciences during the third quarter worth about $253,000. Finally, JPMorgan Chase & Co. lifted its position in Greenwich LifeSciences by 172.0% in the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after buying an additional 4,465 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.